Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action
- 5 October 2020
- journal article
- other
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- Vol. 18 (2) , 187-203
Abstract
Platinum chemotherapy are widely used in first-line treatment of patients with various cancers. PD-1/PD-L1 inhibitors have shown efficacy in several cancers, and the combination of platinum-based c...Keywords
Funding Information
- Doctoral Start-up Foundation of Liaoning Province (20180540024)
- 345 Talent Project of ShengJing Hospital of China Medical University (M0397)
- Organization Department of Liaoning Provincial Party Committee (XLYC1908031)
This publication has 54 references indexed in Scilit:
- Molecular Pathways: The Immunogenic Effects of Platinum-Based ChemotherapeuticsClinical Cancer Research, 2014
- Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and miceJournal of Clinical Investigation, 2011
- Chemotherapy Delivered After Viral Immunogene Therapy Augments Antitumor Efficacy Via Multiple Immune-mediated MechanismsMolecular Therapy, 2010
- Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in miceGut, 2010
- Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in miceJournal of Clinical Investigation, 2010
- Immunogenic death of colon cancer cells treated with oxaliplatinOncogene, 2009
- Chemotherapeutic Agents in Noncytotoxic Concentrations Increase Antigen Presentation by Dendritic Cells via an IL-12-Dependent MechanismThe Journal of Immunology, 2009
- Pretreatment with Cisplatin Enhances E7-Specific CD8+ T-Cell–Mediated Antitumor Immunity Induced by DNA VaccinationClinical Cancer Research, 2008
- Increased expression of CEA and MHC class I in colorectal cancer cell lines exposed to chemotherapy drugsJournal of Cancer Research and Clinical Oncology, 2003
- Cisplatin augments cytotoxic T-lymphocyte–mediated antitumor immunity in poorly immunogenic murine lung cancerThe Journal of Thoracic and Cardiovascular Surgery, 2003